中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 12
Dec.  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(12): 2787-2792

Risk factors for myocardial injury after Nano-Knife surgery in patients with pancreatic cancer

DOI: 10.3969/j.issn.1001-5256.2022.12.019
  • a.

    Department of Anesthesiology, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China

  • b.

    Department of Hepatobiliary Surgery, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China

Research funding:

Medical science and Technology project of Henan Province (LHGJ20190425)

More Information
  • Corresponding author: HU Qiangfu, huli2004803@sina.com (ORCID: 0000-0002-2842-0678)
  • Received Date: 2022-09-30
  • Accepted Date: 2022-11-02
  • Published Date: 2022-12-20
    Abstract
  •   Objective  To investigate the risk factors for myocardial injury after Nano-Knife surgery in patients with pancreatic cancer, and to establish a nomogram model for risk prediction.  Methods  A retrospective analysis was performed for the clinical data of 92 patients with pancreatic cancer who underwent Nano-Knife surgery in The Fifth Affiliated Hospital of Zhengzhou University from September 2020 to November 2021, with serum cardiac troponin I > 0.03 ng/mL within 3 days after surgery as the diagnostic criteria for myocardial injury, the patients were divided into myocardial injury group with 51 patients and non-myocardial injury group with 41 patients. Related baseline data were collected for all patients, including age, sex, body mass index, American Society of Anesthesiologists classification, smoking history, alcohol abuse history, and preoperative comorbidities. The Mann-Whitney U test was used for comparison of continuous data between groups, and the chi-square test or the Fisher's exact test was used for comparison of categorical data between groups. Univariate and multivariate logistic regression analyses were used to screen out the variables with statistical significance, and the factors screened out were used to establish a nomogram for predicting the risk of myocardial injury after Nano-Knife surgery in patients with pancreatic cancer. The receiver operating characteristic (ROC) curve and the area under the ROC curve (AUC) were used to evaluate the discriminatory ability and clinical utility of the model.  Results  Compared with the non-myocardial injury group, the myocardial injury group had a significantly longer ablation time (χ2=7.410, P=0.006), a significantly greater number of probes (χ2=6.130, P=0.047), and a significantly higher proportion of patients with preoperative hypertension (χ2=12.124, P < 0.001) or chronic kidney disease (χ2=12.829, P < 0.001). The univariate logistic regression analysis showed that tumor diameter, ablation time, surgical procedure, number of probes, history of hypertension, and history of chronic kidney disease were associated with the development of myocardial injury (all P < 0.05), and the multivariate logistic regression analysis showed that tumor diameter (odds ratio [OR]= 3.94, 95% confidence interval [CI]: 1.09-14.18, P=0.036), ablation time (OR=4.15, 95%CI: 1.30-13.27, P=0.016), surgical procedure (OR=6.92, 95%CI: 1.92-25.07, P=0.003), and history of hypertension (OR=4.07, 95%CI: 1.12-14.77, P=0.034) were independent risk factors for myocardial injury after Nano-Knife surgery in patients with pancreatic cancer. An AUC of 0.859 showed that the nomogram had good discriminatory ability and clinical utility.  Conclusion  There is a relatively high incidence rate of myocardial injury after Nano-Knife surgery in patients with pancreatic cancer. Preoperative hypertension, tumor diameter > 4 cm, and ablation time > 1 hour are independent risk factors for myocardial injury, and the surgical procedure of Nano-Knife surgery and bypass anastomosis can increase the risk of myocardial injury. The nomogram has a good effect in predicting the risk of myocardial injury.

     

    • FullText(HTML)
  • loading
    • References(18)
  • [1]
    SIEGELl RL, MILLER KD, JEMAL A, et al. Cancer Statistics, 2020[J]. CA Cancer J Clin, 2020, 70(1): 7-30. DOI: 10.3322/caac.21590.
    [2]
    KWON W, THOMAS A, KLUGER MD, et al. Irreversible electroporation of locally advanced pancreatic cancer[J]. Semin Oncol, 2021, 48(1): 84-94. DOI: 10.1053/j.seminoncol.2021.02.004.
    [3]
    HOLLAND MM, BHUTIANI N, KRUSE EJ, et al. A prospective, multi-institution assessment of irreversible electroporation for treatment of locally advanced pancreatic adenocarcinoma: initial outcomes from the AHPBA pancreatic registry[J]. HPB (Oxford), 2019, 21(8): 1024-1031. DOI: 10.1016/j.hpb.2018.12.004.
    [4]
    TIMMER F, GEBOERS B, NIEUWENHUIZEN S, et al. Locally advanced pancreatic cancer: percutaneous management using ablation, brachytherapy, intra-arterial chemotherapy, and intra-tumoral immunotherapy[J]. Curr Oncol Rep, 2021, 23(6): 68. DOI: 10.1007/s11912-021-01057-3.
    [5]
    GARCIA PA, ROSSMEISL JH JR, NEAL NE 2ND, et al. A parametric study delineating irreversible electroporation from thermal damage based on a minimally invasive intracranial procedure[J]. Biomed Eng Online, 2011, 10: 34. DOI: 10.1186/1475-925X-10-34.
    [6]
    KOSTRZEWA M, TUELUEMEN E, RUDIC B, et al. Cardiac impact of R-wave triggered irreversible electroporation therapy[J]. Heart Rhythm, 2018, 15(12): 1872-1879. DOI: 10.1016/j.hrthm.2018.07.013.
    [7]
    LI J, WANG J, ZHANG X, et al. Cardiac impact of high-frequency irreversible electroporation using an asymmetrical waveform on liver in vivo[J]. BMC Cardiovasc Disord, 2021, 21(1): 581. DOI: 10.1186/s12872-021-02412-9.
    [8]
    RUETZLER K, SMILOWITZ NR, BERGER JS, et al. Diagnosis and management of patients with myocardial injury after noncardiac surgery: a scientific statement from the american heart association[J]. Circulation, 2021, 144(19): e287-e305. DOI: 10.1161/CIR.0000000000001024.
    [9]
    NARAYANAN G, BILIMORIA MM, HOSEIN PJ, et al. Multicenter randomized controlled trial and registry study to assess the safety and efficacy of the NanoKnifeⓇ system for the ablation of stage 3 pancreatic adenocarcinoma: overview of study protocols[J]. BMC Cancer, 2021, 21(1): 785. DOI: 10.1186/s12885-021-08474-4.
    [10]
    GEBOERS B, SCHEFFER HJ, GRAYBILL PM, et al. High-voltage electrical pulses in oncology: irreversible electroporation, electrochemotherapy, gene electrotransfer, electrofusion, and electroimmunotherapy[J]. Radiology, 2020, 295(2): 254-272. DOI: 10.1148/radiol.2020192190.
    [11]
    RUARUS A, VROOMEN L, GEBOERS B, et al. Percutaneous irreversible electroporation in locally advanced and recurrent pancreatic cancer (PANFIRE-2): A multicenter, prospective, single-arm, phase Ⅱ study[J]. Radiology, 2020, 294(1): 212-220. DOI: 10.1148/radiol.2019191109.
    [12]
    DU PRÉ BC, VAN DRIEL VJ, van WESSEL H, et al. Minimal coronary artery damage by myocardial electroporation ablation[J]. Europace, 2013, 15(1): 144-149. DOI: 10.1093/europace/eus171.
    [13]
    STILLSTRÖM D, BEERMANN M, ENGSTRAND J, et al. Initial experience with irreversible electroporation of liver tumours[J]. Eur J Radiol Open, 2019, 6: 62-67. DOI: 10.1016/j.ejro.2019.01.004.
    [14]
    DRIGGIN E, MADHAVAN MV, BIKDELI B, et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic[J]. J Am Coll Cardiol, 2020, 75(18): 2352-2371. DOI: 10.1016/j.jacc.2020.03.031.
    [15]
    MORENO MU, EIROS R, GAVIRA JJ, et al. The hypertensive myocardium: from microscopic lesions to clinical complications and outcomes[J]. Med Clin North Am, 2017, 101(1): 43-52. DOI: 10.1016/j.mcna.2016.08.002.
    [16]
    LACKNER I, WEBER B, PRESSMAR J, et al. Cardiac alterations following experimental hip fracture-inflammaging as independent risk factor[J]. Front Immunol, 2022, 13: 895888. DOI: 10.3389/fimmu.2022.895888.
    [17]
    SUGRUE A, VAIDYA V, WITT C, et al. Irreversible electroporation for catheter-based cardiac ablation: a systematic review of the preclinical experience[J]. J Interv Card Electrophysiol, 2019, 55(3): 251-265. DOI: 10.1007/s10840-019-00574-3.
    [18]
    ZHAO K, ZHANG Y, LI J, et al. Modified glucose-insulin-potassium regimen provides cardioprotection with improved tissue perfusion in patients undergoing cardiopulmonary bypass surgery[J]. J Am Heart Assoc, 2020, 9(6): e012376. DOI: 10.1161/JAHA.119.012376.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(5)  / Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (1464) PDF downloads(43) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return